Drug Interaction Report

Fluvoxamine and Buprenorphine: Interaction Details

AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Buprenorphine

Belbuca Brixadi Buprenex BuTrans Simbadol Sublocade Zorbium
+

Fluvoxamine

No brand names on record
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Updated Jul 2, 2026
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 113 documented Fluvoxamine interactions, 92 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
At a glance + Effects may be stronger
The Bottom Line
Fluvoxamine can raise buprenorphine levels (more sedation and breathing risk) and add to serotonin syndrome risk, so your care team may adjust your buprenorphine dose and monitor you more closely. Don't change either medicine on your own; report drowsiness, slowed breathing, or agitation/shivering promptly.

These two medicines can interact in two ways. Fluvoxamine slows down a liver enzyme (CYP3A4) that helps break down buprenorphine. When that enzyme is blocked, buprenorphine can build up in your body, which may cause more sedation, drowsiness, and in some cases slowed breathing.

On top of that, both medicines affect serotonin, a brain chemical. Using them together can raise the small chance of a condition called serotonin syndrome (things like agitation, shivering, sweating, fast heartbeat, or confusion). The good news is that your care team can manage this safely by adjusting your dose and watching you closely. Please don't stop either medicine on your own, just talk with your pharmacist or doctor.

Mechanism: Fluvoxamine is a CYP3A4 inhibitor and reduces buprenorphine metabolism, increasing buprenorphine plasma concentrations and prolonging opioid effects. Both agents are serotonergic, giving additive serotonin syndrome risk. (Buprenorphine is not a prodrug, so inhibition increases, not decreases, its effect.)

  • Direction: increased buprenorphine exposure; additive serotonergic activity.
  • Severity/evidence: major; probable.
  • Monitor: sedation, respiratory depression, and serotonin syndrome (esp. at initiation/titration).
  • Manage: consider reducing buprenorphine dose until stable; on inhibitor discontinuation, consider dose increase and watch for withdrawal. Use a formulation allowing precise titration if needed. Discontinue buprenorphine if serotonin syndrome is suspected.
Onset
unspecified
Evidence
probable
Severity
Major

What happens

An increased risk of serotonin syndrome, increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events

Interaction Deep Dive

Taking buprenorphine together with CYP3A4 inhibitors can raise buprenorphine plasma levels and may result in extended opioid effects. When a patient on buprenorphine requires a CYP3A4 inhibitor, one option is to lower the buprenorphine dose until steady drug effects are reached, along with frequent monitoring for sedation and respiratory depression. Conversely, when stopping a CYP3A4 inhibitor in someone receiving buprenorphine, an increase in the buprenorphine dose may be warranted until stable effects are attained, with monitoring for signs of opioid withdrawal2. If it is not possible to adjust the dosage once the CYP3A4 inhibitor is absent, switch the patient back to a buprenorphine formulation that allows finer dose titration. For patients switched from transmucosal buprenorphine given alongside CYP3A4 inhibitors, confirm through monitoring that the buprenorphine plasma level achieved with subQ buprenorphine is sufficient. For those already receiving subQ buprenorphine who then need a CYP3A4 inhibitor, watch for indications of over-medication. Should buprenorphine toxicity signs and symptoms appear while the co-administered drug cannot be reduced or stopped, decrease the buprenorphine dose. Furthermore, when buprenorphine must be used together with a serotonergic agent, watch the patient for signs and symptoms of serotonin syndrome, particularly at the start of therapy and when adjusting doses; if it is suspected, stop buprenorphine 1.

Why it happens (mechanism)

Additive serotonergic effects; inhibition of CYP3A4-mediated metabolism of buprenorphine

How to manage this interaction

Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is manageable with dose tailoring and closer monitoring.

  • Your buprenorphine dose may need to be adjusted and individualized by your care team, and they may monitor you more closely for excess sedation or slowed breathing.
  • If fluvoxamine is later stopped, your team may adjust buprenorphine again and watch for withdrawal symptoms.
  • Tell your pharmacist or prescriber right away if you notice unusual drowsiness, slow or shallow breathing, or serotonin syndrome signs like agitation, shivering, sweating, fast heartbeat, or confusion.

Management is individual — confirm any change with your pharmacist or prescriber.

Literature reports

1 report — tap to read

a) The impact of concurrently administered CYP3A4 inhibitors on buprenorphine levels in individuals receiving subQ buprenorphine has not been investigated; nevertheless, these interactions have been demonstrated in trials involving transmucosal buprenorphine. Buprenorphine's effects may vary according to the route of administration 1.

Common questions

Can I take Fluvoxamine and Buprenorphine together?

Fluvoxamine can raise buprenorphine levels (more sedation and breathing risk) and add to serotonin syndrome risk, so your care team may adjust your buprenorphine dose and monitor you more closely. Don't change either medicine on your own; report drowsiness, slowed breathing, or agitation/shivering promptly. Always confirm with your pharmacist or prescriber before making any change.

How serious is the Fluvoxamine and Buprenorphine interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How is the Fluvoxamine and Buprenorphine interaction managed?

Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is manageable with dose tailoring and closer monitoring. Your buprenorphine dose may need to be adjusted and individualized by your care team, and they may monitor you more closely for excess sedation or slowed breathing. If fluvoxamine is later stopped, your team may adjust buprenorphine again and… Management is individual — always follow your own care team's guidance.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Questions for your pharmacist

  • Does my dose of Fluvoxamine or Buprenorphine need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (2)

  1. Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
  2. Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Was this write-up helpful?
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.